Head-to-head · Cost-Efficiency Index
Andrew Meds vs Fitish
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Andrew Meds
Shoppers comparing published monthly rates who are willing to check that the price on the page is the price the checkout charges.
Visit Andrew MedsFitish
Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option.
Visit FitishThe verdict
Andrew Meds takes it, leading the Cost-Efficiency Index 70 to 69. Andrew Meds publishes $199 semaglutide and $299 tirzepatide on its product pages, then sends every Get Started button to an intake that sells a $99 low-dose program and never offers tirzepatide at all. Fitish still earns a C — Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Andrew Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Andrew Meds | Fitish |
|---|---|---|
| Cost-Efficiency Index | 70/100 | 69/100 |
| Semaglutide / mo | $199/month month-to-month (the intake this page opens sells a $99 low-dose program instead) | $219/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide / mo | $299/month month-to-month | $339/mo (microdose tier, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $2,628 |
| Tirzepatide / yr (modeled) | $3,588 | $4,068 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #90 | #92 |
Andrew Meds
70/100Where the value is
- Full month-to-month and prepay ladders for both molecules are printed on the product pages, before any intake
- States which pharmacy class fills a prescription — "a 503(A) compounding pharmacy or 503(B) outsourcing facility" — which most sellers at this price leave unsaid
- Names the prescribing practice, with a street address and a direct phone line, in the footer of every page
The tradeoffs
- Three live semaglutide prices disagree: $199 a month on the product page, $99 a month in the intake that page links to, and $149 for a four-week supply in a second funnel
- The tirzepatide page's own funnel offers only semaglutide, so the $299 tirzepatide price cannot be bought through the route the page provides
Fitish
69/100Where the value is
- Price genuinely includes consult, medication, and shipping — confirmed in the product page's own text, not just marketing copy
- A real microdose tier exists at a meaningfully lower fixed price for both drugs
- Injectable and oral tablet formats both offered
The tradeoffs
- No stated minimum commitment or cancellation terms found on the product pages
- No named prescriber, medical director, or specific compounding pharmacy
Regulatory note: the FDA issued a warning letter to FITISH in June 2026. We still list and link to Fitish; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.